Growth Hormone Decreases Visceral Fat and Improves Cardiovascular Risk Markers in Women with Hypopituitarism: A Randomized, Placebo-Controlled Study
Open accessThe DOI matches its Crossref record; 66 of the 67 references it cites were found in a registry or an index.
Abstract
Context Data regarding gender-specific efficacy of GH on critical endpoints are lacking. There are no randomized, placebo-controlled studies of physiological GH therapy solely in women. Objective Our objective was to determine the effects of physiological GH replacement on cardiovascular risk markers and body composition in women with GH deficiency (GHD). Design This was a 6-month, randomized, placebo-controlled, double-blind study. Setting The study was conducted at the General Clinical Research Center. Study participants 43 women with GHD due to hypopituitarism were included in the study. Intervention Study participants were randomized to receive GH (goal mid-normal serum IGF-1) or placebo. Main outcome measures Cardiovascular risk markers, including high-sensitivity C-reactive protein, tissue plasminogen activator, and body composition, including visceral adipose tissue by cross-sectional computed tomography, were measured. Results Mean daily GH dose was 0.67 mg. The mean IGF-1 sd score increased from -2.5 +/- 0.3 to -1.4 +/- 0.9 (GH) (P Conclusions Low-dose GH replacement in women with GHD decreased total and visceral adipose tissue and improved cardiovascular markers, with a relatively modest increase in IGF-1 levels and without worsening insulin resistance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A meta-analyses of 11 randomized trials reported that adult GH replacement resulted in significantly enhanced maximum oxygen uptake and muscle power (169).”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [169]
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Pearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O., Criqui, M., Fadl, Y. Y., Fortmann, S. P., Hong, Y., Myers, G. L., et al. (2003) · Circulation · doi:10.1161/01.cir.0000052939.59093.45 · Cited by 6,401
Katz, A., Nambi, S. S., Mather, K., Baron, A. D., Follmann, D. A., Sullivan, G., & Quon, M. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6661 · Cited by 3,931
Ridker, P. M., Rifai, N., Rose, L., Buring, J. E., & Cook, N. R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021993 · Cited by 3,604
Bonora, E., Targher, G., Alberiche, M., Bonadonna, R. C., Saggiani, F., Zenere, M. B., Monauni, T., & Muggeo, M. (2000) · Diabetes Care · doi:10.2337/diacare.23.1.57 · Cited by 2,456
Premature mortality due to cardiovascular disease in hypopituitarism
Rosén, T., & Bengtsson, B.-Å. (1990) · The Lancet · doi:10.1016/0140-6736(90)91812-o · Cited by 1,402
A, P. T., A, M. G., & W, A. R. (2003) · Journal of Cardiopulmonary Rehabilitation · doi:10.1097/00008483-200305000-00016 · Cited by 1,024
Ridker, P. M., Glynn, R. J., & Hennekens, C. H. (1998) · Circulation · doi:10.1161/01.cir.97.20.2007 · Cited by 1,013
Association between premature mortality and hypopituitarism
Tomlinson, J., Holden, N., Hills, R., Wheatley, K., Clayton, R., Bates, A., Sheppard, M., & Stewart, P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04006-x · Cited by 1,006 · cited 5×
“J Clin Endocrinol Metab, June 2008, 93(6):2063–2071 jcem.”
BackgroundInfluentialTreatment of adults with growth hormone (GH) deficiency with recombinant human GH.
Bengtsson, B. A., Edén, S., Lönn, L., Kvist, H., Stokland, A., Lindstedt, G., Bosaeus, I., Tölli, J., Sjöström, L., & Isaksson, O. G. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.76.2.8432773 · Cited by 778
Kratz (2004) · doi:10.1056/nejmcpc049016 · Cited by 593
The effect of hypopituitarism on life expectancy.
Bates, A. S., Van't Hoff, W., Jones, P. J., & Clayton, R. N. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.3.8772595 · Cited by 475
Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency
Biller, B. M. K., Samuels, M. H., Zagar, A., Cook, D. M., Arafah, B. M., Bonert, V., Stavrou, S., Kleinberg, D. L., Chipman, J. J., & Hartman, M. L. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.5.8509 · Cited by 423 · cited 1×
“Insulin tolerance and GHRH-arginine tests were performed as previously described (36).”
MethodSelf-citationMarkussis, V., Beshyah, S. A., Johnston, D. G., Fisher, C., Nicolaides, A. N., & Sharp, P. (1992) · The Lancet · doi:10.1016/0140-6736(92)92892-j · Cited by 390
The growth hormone deficiency syndrome in adults
Cuneo, R. C., Salomon, F., McGauley, G. A., & Sönksen, P. H. (1992) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1992.tb02347.x · Cited by 375
Novel Inflammatory Markers of Coronary Risk: Theory Versus Practice
Libby, P., & Ridker, P. M. (1999) · Circulation · doi:10.1161/01.cir.100.11.1148 · Cited by 375 · cited 1×
“Each atherosclerotic lesion represents a different stage of a chronic inflammatory process in the arterial wall, and markers along the inflammatory cascade have predicted the risk of cardiovascular events (50).”
BackgroundMaison, P., Griffin, S., Nicoue-Beglah, M., Haddad, N., Balkau, B., & Chanson, P. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030840 · Cited by 362
Cardiovascular risk factors in adult patients with growth hormone deficiency
Rosén, T., Edén, S., Larson, G., Wilhelmsen, L., & Bengtsson, B.-Å. (1993) · Acta Endocrinologica · doi:10.1530/acta.0.1290195 · Cited by 338 · cited 1×
“The GHD syndrome is associated with a cluster of cardiovascular risk factors, including central adiposity (10–12), increased visceral fat (13), insulin resistance (14), dyslipoproteinemia (5, 15), and decreased plasma fibrinolytic activity (16).”
BackgroundEvaluating Novel Cardiovascular Risk Factors: Can We Better Predict Heart Attacks?
Ridker, P. M. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-11-199906010-00018 · Cited by 323
Which Patients Do Not Require a GH Stimulation Test for the Diagnosis of Adult GH Deficiency?
Hartman, M. L. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.2.477 · Cited by 319
Self-citationGrowth Hormone (GH)-Deficient Men Are More Responsive to GH Replacement Therapy Than Women1
Burman, P., Johansson, A. G., Siegbahn, A., Vessby, B., & Karlsson, F. A. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.2.3776 · Cited by 295 · cited 3×
“(1), who performed a randomized, placebo-controlled study of GH administration in 21 men and 15 women.”
BackgroundWeaver, J. U. (1995) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.80.1.153 · Cited by 282 · cited 1×
“The GHD syndrome is associated with a cluster of cardiovascular risk factors, including central adiposity (10–12), increased visceral fat (13), insulin resistance (14), dyslipoproteinemia (5, 15), and decreased plasma fibrinolytic activity (16).”
BackgroundSmith, S. C., Jr. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/edxm-hp68 · Cited by 281
Baum, H. B. A., Biller, B. M. K., Finkelstein, J. S., Cannistraro, K. B., Oppenheim, D. S., Schoenfeld, D. A., Michel, T. H., Wittink, H., & Klibanski, A. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-11-199612010-00003 · Cited by 277
Self-citationGrowth hormone-deficient adults are insulin-resistant
Johansson, J.-O., Fowelin, J., Landin, K., Lager, I., & Bengtsson, B.-Å. (1995) · Metabolism · doi:10.1016/0026-0495(95)90004-7 · Cited by 275 · cited 1×
“The GHD syndrome is associated with a cluster of cardiovascular risk factors, including central adiposity (10–12), increased visceral fat (13), insulin resistance (14), dyslipoproteinemia (5, 15), and decreased plasma fibrinolytic activity (16).”
BackgroundAimaretti, G., Corneli, G., Razzore, P., Bellone, S., Baffoni, C., Arvat, E., Camanni, F., & Ghigo, E. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.5.4837 · Cited by 272
Böger, R. H., Skamira, C., Bode-Böger, S. M., Brabant, G., von zur Muhlen, A., & Frolich, J. C. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119095 · Cited by 270
Growth Hormone (GH) Treatment Reverses Early Atherosclerotic Changes in GH-Deficient Adults1
Pfeifer, M., Verhovec, R., Zizek, B., Prezelj, J., Poredos, P., & Clayton, R. N. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.2.5456 · Cited by 260
Sesmilo, G., Biller, B. M. K., Llevadot, J., Hayden, D., Hanson, G., Rifai, N., & Klibanski, A. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-2-200007180-00010 · Cited by 257
Self-citationKoutkia, P., Canavan, B., Breu, J., Torriani, M., Kissko, J., & Grinspoon, S. (2004) · JAMA · doi:10.1001/jama.292.2.210 · Cited by 215
Fowelin, J., Attvall, S., Lager, I., & Bengtsson, B.-Å. (1993) · Metabolism · doi:10.1016/0026-0495(93)90197-v · Cited by 200
Growth Hormone (GH)-Deficient Men Are More Responsive to GH Replacement Therapy Than Women
Burman, P. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.2.550 · Cited by 198
De Boer, H. (1992) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.75.3.833 · Cited by 182
Reduced Longevity in Untreated Patients with Isolated Growth Hormone Deficiency
Besson, A., Salemi, S., Gallati, S., Jenal, A., Horn, R., Mullis, P. S., & Mullis, P. E. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021938 · Cited by 168
High fibrinogen and plasminogen activator inhibitor activity in growth hormone-deficient adults.
Johansson, J. O., Landin, K., Tengborn, L., Rosén, T., & Bengtsson, B. A. (1994) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.14.3.434 · Cited by 167 · cited 2×
“The GHD syndrome is associated with a cluster of cardiovascular risk factors, including central adiposity (10–12), increased visceral fat (13), insulin resistance (14), dyslipoproteinemia (5, 15), and decreased plasma fibrinolytic activity (16).”
BackgroundGrowth Hormone (GH) Treatment Reverses Early Atherosclerotic Changes in GH-Deficient Adults
Pfeifer, M. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.2.453 · Cited by 160
Body composition in growth hormone deficient adults
Binnerts, A., Deurenberg, P., Swart, G., Wilson, J., & Lamberts, S. W. J. (1992) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/55.5.918 · Cited by 159
Wüster, C., Slenczka, E., & Ziegler, R. (1991) · Journal of Molecular Medicine · doi:10.1007/bf01797616 · Cited by 151
Effects of Seven Years of GH-Replacement Therapy on Insulin Sensitivity in GH-Deficient Adults
Svensson, J., Fowelin, J., Landin‐Wilhelmsen, K., Bengtsson, B., & Johansson, J.-O. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.5.2121 · Cited by 145 · cited 1×
“Insulin resistance is a well-established risk factor for the development of cardiovascular disease and can be exacerbated acutely by GH administration, whereas chronic effects appear to be neutral or positive (24, 57, 58).”
BackgroundBülow, B., Hagmar, L., Eskilsson, J., & Erfurth, E. M. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.2.6346 · Cited by 142 · cited 1×
“Because hypopituitarism carries a greater risk of mortality in women than in men (4, 6, 7), investigation into the pathophysiology of atherosclerosis in women with hypopituitarism may have important clinical implications.”
BackgroundIncreased Arterial Intima-Media Thickness in Childhood-Onset Growth Hormone Deficiency
Capaldo, B. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.5.1378 · Cited by 139
Span, J. P. T., Pieters, G. F. F. M., Sweep, C. G. J., Hermus, A. R. M. M., & Smals, A. G. H. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.3.6463 · Cited by 132 · cited 1×
“Moreover, in both healthy (47) and hypopituitary (48) women, IGF-1 levels are lower for a given level of GH secretion than in their male counterparts.”
BackgroundEndothelial dysfunction in hypopituitary adults with growth hormone deficiency
Evans, M., Davies, Goodfellow, Rees, & Scanlon (1999) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1999.00671.x · Cited by 129
Borson-Chazot, F., Serusclat, A., Kalfallah, Y., Ducottet, X., Sassolas, G., Bernard, S., Labrousse, F., Pastene, J., Sassolas, A., Roux, Y., et al. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.4.5595 · Cited by 128
Serri, O., St-Jacques, P., Sartippour, M., & Renier, G. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.1.5374 · Cited by 100
Inflammatory cardiovascular risk markers in women with hypopituitarism
Sesmilo, G., Miller, K. K., Hayden, D., & Klibanski, A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.12.8087 · Cited by 97
Self-citationBulow, B. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.2.574 · Cited by 92
Johansson, J.-O., Landin, K., Johannsson, G., Tengborn, L., & Bengtsson, B.-Å. (1996) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1650594 · Cited by 81 · cited 2×
“other pathways, including clotting factors (26), but these studies have focused primarily on men.”
BackgroundBollerslev, J., Ueland, T., Jørgensen, A. P., Fougner, K. J., Wergeland, R., Schreiner, T., & Burman, P. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02125 · Cited by 77 · cited 2×
“In a study of men and women combined, a 41% decrease in high-sensitivity C-reactive protein was subsequently demonstrated (29).”
BackgroundResultGrowth Hormone and Insulinlike Growth Factor I Enhance Host Defense in a Murine Sepsis Model
Inoue, T. (1995) · Archives of Surgery · doi:10.1001/archsurg.1995.01430100093018 · Cited by 69
Yuen, K. C. J., Frystyk, J., White, D. K., Twickler, T. B., Koppeschaar, H. P. F., Harris, P. E., Fryklund, L., Murgatroyd, P. R., & Dunger, D. B. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02359.x · Cited by 67
Serri, O. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.58 · Cited by 67
Christ, E. R., Cummings, M. H., Albany, E., Umpleby, A. M., Lumb, P. J., Wierzbicki, A. S., Naoumova, R. P., Boroujerdi, M. A., Sönksen, P. H., & Russell-Jones, D. L. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.1.5365 · Cited by 62
Growth Hormone Attenuates the Acute-Phase Response to Thermal Injury
Jarrar, D. (1997) · Archives of Surgery · doi:10.1001/archsurg.1997.01430350021003 · Cited by 55
Sesmilo, G., Biller, B. M. K., Llevadot, J., Hayden, D., Hanson, G., Rifai, N., & Klibanski, A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.4.7387 · Cited by 53
Self-citationKvasnička, J., Marek, J., Kvasnička, T., Weiss, V., Marková, M., Štìěpán, J., & Umlaufová, A. (2000) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2000.01002.x · Cited by 53
Calculation of energy expenditure from indirect calorimetry: assessment of the Weir equation.
Cunningham, J. J. (1990) · PubMed · Cited by 52
Insulin-Like Growth Factor I Levels in Healthy Adults
Landin-Wilhelmsen, K., Lundberg, P.-A., Lappas, G., & Wilhelmsen, L. (2004) · Hormone Research in Paediatrics · doi:10.1159/000080753 · Cited by 51 · cited 1×
“Moreover, in both healthy (47) and hypopituitary (48) women, IGF-1 levels are lower for a given level of GH secretion than in their male counterparts.”
BackgroundLeonsson, M., Hulthe, J., Oscarsson, J., Johannsson, G., Wendelhag, I., Wikstrand, J., & Bengtsson, B. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01663.x · Cited by 49
Borson‐Chazot, F. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.4.1329 · Cited by 49
Geffner, M. (1997) · Acta Paediatrica · doi:10.1111/j.1651-2227.1997.tb18377.x · Cited by 40
Sesmilo, G. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.4.1518 · Cited by 39
Christ, E. R. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.307 · Cited by 37
Erfurth, E. M., Bülow, B., ESKILSSON, J., & Hagmar, L. (1999) · Growth Hormone & IGF Research · doi:10.1016/s1096-6374(99)80005-7 · Cited by 30
Growth Hormone Increases Vascular Cell Adhesion Molecule 1 Expression:in Vivoandin VitroEvidence
Hansen, T. K., Fisker, S., Dall, R., Ledet, T., Jørgensen, J. O. L., & Rasmussen, L. M. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030223 · Cited by 23
Research works printed but not linked: 1
- Wuster, 1991, Klin Wochenschr, 769
Cited by
Pathophysiology of human visceral obesity: an update
Tchernof, A., & Després, J.-P. (2013) · Physiological Reviews · doi:10.1152/physrev.00033.2011 · Cited by 2,583
“Nevertheless, several studies including randomized placebo-controlled studies have now shown beneficial effects of GH therapy on visceral fat accumulation and related outcomes in various populations (33, 161, 412, 527, 528).”
BackgroundHormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2118 · Cited by 945
Ismail, I., Keating, S. E., Baker, M. K., & Johnson, N. A. (2012) · Obesity Reviews · doi:10.1111/j.1467-789x.2011.00931.x · Cited by 345
“GH acts to stimulate adipose tissue directly via hormone sensitive lipase and also indirectly by enhancing insulin sensitivity (56,57).”
BackgroundYuen, K. C. J., Biller, B. M. K., Radovick, S., Carmichael, J. D., Jasim, S., Pantalone, K. M., & Hoffman, A. R. (2019) · Endocrine Practice · doi:10.4158/gl-2019-0405 · Cited by 298
Self-citationRole of the GH/IGF-1 axis in lifespan and healthspan: Lessons from animal models
Berryman, D. E., Christiansen, J. S., Johannsson, G., Thorner, M. O., & Kopchick, J. J. (2008) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2008.05.005 · Cited by 288
Metadata
- Authors
- Beauregard, C., Utz, A. L., Schaub, A. E., Nachtigall, L., Biller, B. M. K., Miller, K. K., & Klibanski, A.
- Affiliations
- Harvard University (US)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2008-06-01
- Volume
- 93
- Issue
- 6
- Pages
- 2063-2071
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC2435650
- OpenAlex
- W1968009970
- Cited by
- 99
- References
- 67
- Citations by year
- 2025: 3 · 2023: 2 · 2022: 3 · 2021: 2 · 2020: 5 · 2019: 1 · 2018: 8 · 2017: 9 · 2016: 4 · 2015: 3 · 2014: 11 · 2013: 8 · 2012: 9
- FWCI
- 7.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK040561)
- National Center for Research Resources (M01RR001066, M01-RR01066)
- NIH Clinical Center
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Keywords
- growth hormone replacement therapy, growth hormone deficiency, hypopituitarism, women, visceral adipose tissue, body composition, cardiovascular risk markers, C-reactive protein, tissue plasminogen activator, insulin-like growth factor I, insulin resistance, cholesterol, HDL cholesterol, inflammation, fat loss
- MeSH terms
- Adult, Aged, Body Composition, Cardiovascular Diseases, Double-Blind Method, Female, Glucose, Humans, Hypopituitarism, Insulin-Like Growth Factor I, Lipids, Lipoproteins, Middle Aged, Placebos, Risk Factors, Growth Hormone, Biomarkers, Human Growth Hormone, Intra-Abdominal Fat
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.